Phase 1 Rheumatoid Arthritis Trial, Recruiting NCT07258849 Sponsor: Eli Lilly and Company Condition: Rheumatoid Arthritis
Back to Rheumatoid Arthritis

Phase 1 Rheumatoid Arthritis Trial, Recruiting

NCT07258849
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People with a body mass index (BMI) between 18.0 and 32.0 (a measure of body weight relative to height), inclusive — this applies to certain parts of the trial only
  • People taking part in Parts C and D of the trial must weigh at least 50 kilograms and have a BMI between 18.0 and 40.0, inclusive
  • People taking part in Parts C and D must have been diagnosed with rheumatoid arthritis (a condition where the immune system attacks the joints) as an adult, for at least 3 months before joining the trial

Who may not be able to join:

  • Healthy participants in Parts A and B: People who have had, or currently have, serious conditions affecting the heart, lungs, liver, eyes, kidneys, digestive system, hormones, blood, nervous system, or mental health, where those conditions could affect how the body processes medicines
  • People with rheumatoid arthritis in Parts C and D: Those whose rheumatoid arthritis has been classified as "Class 4" — the most severe category — according to established medical guidelines
  • People with rheumatoid arthritis in Parts C and D: Those who show an abnormal result on a heart electrical activity test (called an ECG) at the screening stage
  • People with rheumatoid arthritis in Parts C and D: Those who currently have, or have recently had, an active infection

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Phone: 1-317-615-4559

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
2 December 2025
Est. completion
1 March 2028

Where this trial is recruiting

🇩🇪 Germany 🇺🇸 United States

Primary endpoints

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov